XML 22 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Operating activities      
Net loss $ (27,364) $ (36,060) $ (32,630)
Reconciliation of net loss to net cash used in operating activities:      
Depreciation and amortization 304 395 202
Stock-based compensation expense 2,007 2,160 1,658
Accretion of discount/premium on investment securities 26 148  
Non-cash interest expense 155 277 293
Gain on sale of fixed assets (30) (52)  
Changes in assets and liabilities:      
Prepaid expenses and other current assets (93) (229) (450)
Other assets     2
Accounts payable (632) 77 196
Accrued expenses (1,215) 418 954
Deferred rent 6 8 (18)
Net cash used in operating activities (26,836) (32,858) (29,793)
Investing activities      
Purchases of available-for-sale securities   (45,539)  
Sales and maturities of available-for-sale securities 14,910 30,456  
Purchases of property and equipment (57) (459) (421)
Sale of property and equipment 30 52  
Net cash provided by (used in) investing activities 14,883 (15,490) (421)
Financing activities      
Proceeds from initial public offering, net of issuance costs     61,744
Proceeds from issuance of preferred stock, net of issuance costs     12,331
Proceeds from registered direct offering, net of issuance costs   10,603  
Proceeds from at-the-market offering, net of issuance costs 8,036 1,391  
Proceeds from exercise of common stock options and warrants 23 503 91
Proceeds from borrowing     5,000
Payments on borrowing (3,333) (3,333) (833)
Debt issuance costs     (7)
Net cash provided by financing activities 4,726 9,164 78,326
Net (decrease) increase in cash and cash equivalents (7,227) (39,184) 48,112
Cash and cash equivalents, beginning of period 23,596 62,780 14,668
Cash and cash equivalents, end of period 16,369 23,596 62,780
Supplemental disclosure of cash flow information      
Cash paid for interest $ 327 $ 582 684
Non-cash financing activities      
Warrants for the purchase of series B preferred stock issued in conjunction with credit facility     107
Initial public offering costs in accounts payable and accrued liabilities     (492)
Reclassification of deferred IPO costs from non-current assets to additional paid-in capital     1,787
Reclassification of warrant liability to additional paid-in capital     $ 206